Next 10 |
Company to host conference call and webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. A...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted Priority Review for Acadia’s submission. “Re...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring DAYBUE™ (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (AAN) 2024 annual meeting, being held this week in Denver, CO. The presentations inclu...
2024-04-11 14:10:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures. Several major pharmac...
2024-04-09 15:16:37 ET More on Taysha Gene Therapies Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript Taysha Gene Therapies, Inc. 2023 Q4 - Results - Earnings Call Presentation ...
2024-04-09 11:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead research and development at Acadia and serve as a member of the company’s Executive Leadership ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the 23 rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 3:45 p.m. Eastern Time. The conference will be held virtually. A live webcast of Acadia’s fir...
2024-03-26 14:13:56 ET Summary Neurogene Inc., a clinical-stage company focused on genetic medicines for rare neurological diseases, has seen a significant increase in its share price since joining the Nasdaq in December 2023. The company is progressing two drug candidates, NGN-40...
NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acadia Pharmaceuticals Inc. ("Acadia " or "the Company") (NASDAQ:ACAD). Investors who purchased Acadia securities prior to September 9, 2019, and conti...
News, Short Squeeze, Breakout and More Instantly...
ACADIA Pharmaceuticals Inc. Company Name:
ACAD Stock Symbol:
NASDAQ Market:
ACADIA Pharmaceuticals Inc. Website:
Company to host conference call and webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. A...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted Priority Review for Acadia’s submission. “Re...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring DAYBUE™ (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (AAN) 2024 annual meeting, being held this week in Denver, CO. The presentations inclu...